Evidence mapPaperPMID 41257227Full record

ArticleDiabetes spectrum : a publication of the American Diabetes Association2025

Optimizing Automated Insulin Delivery Systems for Pregnancy.

Emily D Szmuilowicz, Denice S Feig

Abstract read
In one paragraph

Article in Diabetes spectrum : a publication of the American Diabetes Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Perinatal Diabetes Care.Diabetes spectrum : a publication of the American Diabetes Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emily D SzmuilowiczDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.ORCID https://orcid.org/0000-0002-7399-3934
Denice S FeigDepartments of Obstetrics and Gynaecology and Health Policy, Management and Evaluation, Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Automated insulin delivery (AID) systems have revolutionized modern diabetes care outside of pregnancy, but none of the AID systems currently available in the U.S. are approved for use during pregnancy, none have glucose targets low enough to achieve the stricter fasting glucose targets recommended during pregnancy, and none have algorithms that were designed to respond to the amplified oscillations in glycemia that occur in pregnancy or the progressive changes in insulin resistance observed over the course of gestation. Despite these limitations, many women elect to continue using AID off label during pregnancy based on consideration of individual clinical factors and preferences. This article presents some commonly encountered challenges to off-label AID use and CGM interpretation during pregnancy, along with suggested best-practice workarounds to optimize the care of pregnant individuals with diabetes using AID.

Identifiers

PMID41257227
PMCPMC12620746

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.